Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China flag China · Delayed Price · Currency is CNY
40.10
+0.06 (0.15%)
Oct 30, 2026, 3:04 PM CST

Betta Pharmaceuticals Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Operating Revenue
3,7713,5782,8272,4172,3422,206
Other Revenue
31.6731.6764.9539.4134.1840.05
3,8023,6092,8922,4562,3772,246
Revenue Growth
16.47%24.81%17.74%3.35%5.82%20.08%
Cost of Revenue
926.7738.66538.52404.48268.69174.44
Gross Profit
2,8762,8712,3532,0522,1082,071
Selling, General & Admin
1,7721,7791,3631,1161,2341,141
Research & Development
461.48510.87501.9640.14699.9565.95
Other Operating Expenses
45.9240.8818.1910.62-34.5115.24
Operating Expenses
2,2872,3301,8761,7721,9011,723
Operating Income
588.26540.45476.96279.88206.96348.77
Interest Expense
-72.8-76.14-45.49-54.95-195.8-15.78
Interest & Investment Income
1.834.296.7810.2310.8833.35
Currency Exchange Gain (Loss)
-12.62-12.624.146.729.55-3.63
Other Non Operating Income (Expenses)
-18.61-1.19-6.57-4.96-9-0.84
EBT Excluding Unusual Items
486.06454.79435.82236.9222.59361.88
Gain (Loss) on Sale of Investments
30.13-79.33-40.97-13.67-20.621.01
Gain (Loss) on Sale of Assets
-0.340.38-0.59-0.0188.610.07
Asset Writedown
-152.47-0.01-28.05-1.07-3.01-0.03
Other Unusual Items
38.5338.5327.9599.9-27.01
Pretax Income
401.9414.36394.16322.0787.57389.93
Income Tax Expense
151.13128.157.18-11.54-37.1910.37
Earnings From Continuing Operations
250.77286.21386.98333.62124.76379.56
Minority Interest in Earnings
15.8919.1215.5914.4220.663.51
Net Income
266.66305.33402.57348.03145.42383.07
Net Income to Common
266.66305.33402.57348.03145.42383.07
Net Income Growth
-12.07%-24.15%15.67%139.33%-62.04%-36.83%
Shares Outstanding (Basic)
422418419419416416
Shares Outstanding (Diluted)
422418419419416416
Shares Change
0.18%-0.26%0.01%0.72%-0.02%2.32%
EPS (Basic)
0.630.730.960.830.350.92
EPS (Diluted)
0.630.730.960.830.350.92
EPS Growth
-12.23%-23.96%15.66%137.47%-62.01%-38.26%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Free Cash Flow
312.48294.5883.58-181.79-703.8-231.75
Free Cash Flow Per Share
0.740.700.20-0.43-1.69-0.56
Dividend Per Share
0.1500.1500.2000.1700.0700.250
Dividend Growth
-25.00%-25.00%17.65%142.86%-72.00%-19.36%
Gross Margin
75.63%79.53%81.38%83.53%88.69%92.23%
Operating Margin
15.47%14.97%16.49%11.39%8.71%15.53%
Profit Margin
7.01%8.46%13.92%14.17%6.12%17.06%
Free Cash Flow Margin
8.22%8.16%2.89%-7.40%-29.61%-10.32%
EBITDA
1,2711,088845.1578.14453.58517.89
EBITDA Margin
33.43%30.15%29.22%23.54%19.09%23.06%
D&A For EBITDA
682.77547.93368.14298.26246.62169.12
EBIT
588.26540.45476.96279.88206.96348.77
EBIT Margin
15.47%14.97%16.49%11.39%8.71%15.53%
Effective Tax Rate
37.60%30.93%1.82%--2.66%
Revenue as Reported
3,8023,6092,8922,4562,3772,246
Advertising Expenses
----414.75459.29